PMID: 2897212Mar 1, 1988Paper

Pharmacokinetics of indoramin and its 6-hydroxylated metabolite after repeated oral dosing

Biopharmaceutics & Drug Disposition
D M PierceR A Franklin

Abstract

The pharmacokinetics of indoramin and its active 6-hydroxylated metabolite have been studied in healthy male volunteers after repeated oral dosing with 37.5 mg twice daily for 2 weeks. Plasma concentrations of indoramin accumulated, on average, three to four-fold above those anticipated on the basis of the kinetics after the first dose, though steady state was achieved by the end of the first week and no further increase was observed after 2 weeks. The degree of accumulation was consistent between subjects, with a highly significant (p less than 0.001) correlation between the concentration 2 h after a single dose and the average steady-state concentration. Possible explanations for the accumulation of indoramin are discussed. Plasma concentrations of 6-hydroxyindoramin, in contrast, did not accumulate on multiple dosing. At steady state, concentrations of the metabolite, as represented by the AUC0-8h, were approximately 30-40 per cent of those of the unchanged drug. Since the two compounds are approximately equipotent the metabolite may accounts for 25 per cent of the hypotensive activity of indoramin during a typical clinical regime of 37.5 mg twice daily.

References

Oct 1, 1978·British Journal of Clinical Pharmacology·A J WoodD G Shand
Dec 1, 1978·Clinical Pharmacology and Therapeutics·T WalleT E Gaffney
Jun 1, 1976·British Journal of Clinical Pharmacology·G H DraffanC T Dollery
Jan 1, 1987·European Journal of Clinical Pharmacology·D M PierceR A Franklin
Sep 18, 1965·Nature·J G WagnerO S Carpenter
Jan 1, 1984·Clinical Pharmacokinetics·S M Pond, T N Tozer
Jan 1, 1984·European Journal of Clinical Pharmacology·H M NorburyS J Warrington
Jan 1, 1983·European Journal of Clinical Pharmacology·H M NorburyS J Warrington
May 1, 1983·British Journal of Clinical Pharmacology·S HassanP Turner
Jan 1, 1983·European Journal of Clinical Pharmacology·R A FranklinD Stevenson
Aug 1, 1982·Clinical Pharmacology and Therapeutics·J G WagnerJ Vasiliades
Jan 1, 1982·Current Medical Research and Opinion·G N VolansT Frost
Nov 1, 1981·Clinical Pharmacology and Therapeutics·S B FreedmanD T Kelly

Citations

Jan 1, 1988·European Journal of Clinical Pharmacology·D M PierceR A Franklin
Dec 1, 1990·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·D M Pierce

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Hereditary Sensory Autonomic Neuropathy

Hereditary Sensory Autonomic Neuropathies are a group of inherited neurodegenerative disorders characterized clinically by loss of sensation and autonomic dysfunction. Here is the latest research on these neuropathies.

Spatio-Temporal Regulation of DNA Repair

DNA repair is a complex process regulated by several different classes of enzymes, including ligases, endonucleases, and polymerases. This feed focuses on the spatial and temporal regulation that accompanies DNA damage signaling and repair enzymes and processes.

Glut1 Deficiency

Glut1 deficiency, an autosomal dominant, genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier, is characterized by mental and motor developmental delays and infantile seizures. Follow the latest research on Glut1 deficiency with this feed.

Separation Anxiety

Separation anxiety is a type of anxiety disorder that involves excessive distress and anxiety with separation. This may include separation from places or people to which they have a strong emotional connection with. It often affects children more than adults. Here is the latest research on separation anxiety.

KIF1A Associated Neurological Disorder

KIF1A associated neurological disorder (KAND) is a rare neurodegenerative condition caused by mutations in the KIF1A gene. KAND may present with a wide range and severity of symptoms including stiff or weak leg muscles, low muscle tone, a lack of muscle coordination and balance, and intellectual disability. Find the latest research on KAND here.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.